Emerging and Current Infectious Diseases in the Critical Care Setting

Credit

Planning Committee Disclosure - No relevant relationships

All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners.  For speaker disclosures, please see the faculty biography.

Handouts/Brochure

Speaker

Paul Langlois, APN, PhD, CCRN, CCNS Related seminars and products

---

Paul Langlois, APN, PhD, CCRN, CCNS, is a critical care clinical specialist in the surgical, medical, neurologic, burn, CCU, and trauma ICUs of Cook County Hospital, Chicago. Drawing on over 40 years of experience assessing and managing patients with life-threatening diseases, Dr. Langlois provides advanced-level training to nurses, physician assistants, nurse practitioners, respiratory therapists, and physicians.

Dr. Langlois is committed to providing the highest quality of care to patients through advanced education. His presentations are evidence-based, timely, and provide participants with numerous case studies to facilitate critical thinking. As a bedside clinical nurse specialist, he has developed several institution-wide protocols for the multidisciplinary assessment and management of infectious disease and multi-system organ failure patients.

His presentations are enthusiastically delivered and offer highly practical tips that help make the most challenging concepts easy to understand. Linking knowledge to clinical practice is the goal of every educational program.  

 

Speaker Disclosures:
Financial: Dr. Paul Langlois has employment relationship with Cook County Hospital and Emergency Care Consultants. He receives a speaking honorarium and recording royalties from PESI, Inc. He has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Paul Langlois is a member of the American Nurses Association, the American Association of Critical Care Nurses, and the Society of Critical Care Medicine.

Additional Info

Access never expires for this product.

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info

Objectives

1. Differentiate the medications which are used to manage the patient with COVID-19.
2. Analyze the current methods to detect and treat monkeypox from other viruses of the genus orthopoxvirus.
3. Create a medication regimen for a tuberculosis patient, both newly diagnosed and with drug-resistant tuberculosis.
4. Distinguish Hepatitis A, B and C based upon their recognition and treatment.
5. Formulate a differential diagnosis for a patient with suspected influenza.

Outline

• Pathophysiology of SARS-CoV2/COVID-19
• Why so many variants?
• Laboratory parameters for SARS-CoV2
• Effectiveness of all the COVID-19 vaccines
• Antiviral medications:  FDA approved vs. those in clinical trials
• Long-COVID-19 signs and symptoms

• Where did it originate?
• Diagnostics
• Prevalence in the USA
• Infection control measures
• Medications: FDA approved and investigational
• Vaccine priorities

• Prevalence is rising in the USA
• Patient history and presenting signs and symptoms
• Diagnostic tests
• Treatments and vaccines

• What is Mycobacterium tuberculosis and how is it detected?
• Newly diagnosed- and multi-drug resistant-TB in these geographic areas
• First line medications for drug susceptible TB (doses, how often and how long to take)
• Multi-drug resistant TB treatments

• Differentiating influenza from other conditions
• Prophylactic medications
• Antiviral treatments
• Why do we need an annual influenza vaccine?
• Combination COVID and influenza vaccine

Target Audience

• Nurses
• Nurse Practitioners
• Clinical Nurse Specialists
• Physician Assistants